BLA 761039 · Coherus Biosciences INC
Udenyca
Pegfilgrastim-Cbqv · Injection · Leukocyte Growth Factor
Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 2, 2018
Approved uses
4
Original approval plus efficacy supplements
Registered trials
400
72 Phase 3, 30 recruiting
FAERS reports
1,434
291 serious, 130 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 23, 2026.
UDENYCA is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy UDENYCA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies ( 14.1 )] . Limitations of Use UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome UDENYCA is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )] .
Mechanism: Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 2023 Supplement 15 · Efficacy LabelLetter
- Mar 3, 2023 Supplement 13 · Efficacy LabelLetter
- Nov 28, 2022 Supplement 14 · Efficacy LetterLabel
- Nov 2, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
- UDENYCA · PEGFILGRASTIM-CBQV 6MG/0.6ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegfilgrastim" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryPivotal-lookingStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00301925 · 4,400 participants (planned) · Start Dec 16, 2005 · Primary completion Sep 2024
Drug: pegfilgrastim; capecitabine and 4 more · For: Breast Cancer
Sites: Ashford-Kent, United Kingdom; Ashington, United Kingdom; Ashton-under-Lyne, United Kingdom · 152 sites in all
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT00070564 · 3,294 participants · Start Nov 2003 · Primary completion Jan 2015
Drug: pegfilgrastim; AC regimen and 3 more · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 542 sites in all
- Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast CancerPivotal-lookingActive, not recruiting
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyAcademic, hospital or other
NCT00433420 · 2,000 participants (planned) · Start Apr 2003 · Primary completion May 2006
Drug: pegfilgrastim; cyclophosphamide and 3 more · For: Breast Cancer
- TAC Versus TC for Adjuvant Breast CancerPivotal-lookingCompleted
US Oncology ResearchIndustry
NCT00493870 · 1,961 participants · Start May 29, 2007 · Primary completion May 31, 2015
Drug: Docetaxel; Doxorubicin and 1 more · For: Breast Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Sedona, Arizona · 95 sites in all
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00887536 · 1,613 participants · Start May 2009 · Primary completion Feb 2018
Drug: bevacizumab; docetaxel and 3 more · For: Breast Cancer
Sites: Bessemer, Alabama; Birmingham, Alabama; Huntsville, Alabama · 533 sites in all
- Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial CancerPivotal-lookingCompleted
GOG FoundationResearch network
NCT00063999 · 1,381 participants · Start Aug 25, 2003 · Primary completion Jun 29, 2013
Drug: Carboplatin; Cisplatin and 4 more · For: Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7 and 3 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 650 sites in all
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60aPivotal-lookingCompleted
University of LeipzigAcademic, hospital or other
NCT01497002 · 1,222 participants · Start Apr 2005 · Primary completion Jul 18, 2018
Drug: Cytarabine; human stem cells · For: Acute Myeloid Leukaemia
Sites: Leipzig, Germany
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00678327 · 1,202 participants · Start Aug 29, 2008 · Primary completion Jan 31, 2016
Drug: bleomycin sulfate; filgrastim and 9 more · For: Lymphoma
Sites: Southampton, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device malfunction915
- no adverse event715
- product dose omission issue159
- death99
- accidental exposure to product39
- device failure38
- product label confusion36
- neutrophil count decreased30
- device leakage24
- bone pain21
- nausea20
- white blood cell count decreased19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 78 |
| 2020 | 119 |
| 2021 | 68 |
| 2022 | 55 |
| 2023 | 30 |
| 2024 | 272 |
| 2025 | 358 |
| 2026 | 454 |
Recalls
1 FDA enforcement reports for this application.
Jan 16, 2026 · Class I · Ongoing
Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Udenyca (PEGfilgrastim-Cbqv)
2024 spending
$13.4M
Beneficiaries
962
2,873 claims
Per beneficiary
$13,959
$6,598.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,343,087 |
| 2021 | $8,381,827 |
| 2022 | $6,204,814 |
| 2023 | $7,543,946 |
| 2024 | $13,428,171 |
Part B: Udenyca* (Pegfilgrastim-Cbqv*) · HCPCS Q5111
2024 spending
$91.0M
Beneficiaries
16,032
52,151 claims
Per beneficiary
$5,677
2024 ASP limit $141.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $228,110,103 |
| 2021 | $160,042,880 |
| 2022 | $88,617,866 |
| 2023 | $67,282,230 |
| 2024 | $91,015,072 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS, Bohlius J, Cameron DA, et al. · Eur J Cancer 2011 · Consensus Statement, Practice Guideline
- Same-day pegfilgrastim and chemotherapy.
Lokich J · Cancer Invest 2005 · Clinical Trial, Research Support, Non-U.S. Gov't
- Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial.
Li P, Chen Y, Lin Y, et al. · Ann Intern Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Jaramillo S, Benner A, Krauter J, et al. · Blood Cancer J 2017 · Comparative Study, Multicenter Study
- Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Barrett JA, Greene D, Lakshmikanthan S, et al. · J Clin Pharmacol 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Coherus Biosciences INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.